Phase II trial of pegylated liposomal doxorubicin in combination with gemcitabine in metastatic breast cancer patients

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 35, Issue 1, 2012, Pages 18-21

  Jacquin, Jean Philippe ^a   Chargari, Cyrus ^d   Thorin, Julie ^b   Mille, Dominique ^a   Mélis, Adrien ^a   Orfeuvre, Hubert ^g   Clavreul, Guillaume ^h   Chaigneau, Loic ^b   Nourissat, Alice ^e   Dumanoir, Chantal ^e   Savary, Jacqueline ^f   Merrouche, Yacine ^a   Magné, Nicolas ^c  

^a Department of Medical Oncology ^*  (France)

^b Statistical Unit   (France)

^c Institut de Cancerologie de la Loire   (France)

^d Hôpital d'instruction de Armées du Val de Grâce   (France)

^e Laboratoire Schering Plough   (France)

^f Laboratoire Elli Lilly   (France)

^g Centre Hospitalier de Bourg en Bresse   (France)

^h UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

breast cancer patients; first line chemotherapy; gemcitabine; pegylated liposomal doxorubicin; phase II trial

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE;

ADJUVANT THERAPY; ADULT; ALOPECIA; ANEMIA; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HUMAN; INFECTION; METASTATIC BREAST CANCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HAND-FOOT SYNDROME; HUMANS; INJECTIONS, INTRAVENOUS; MIDDLE AGED; NEUTROPENIA; POLYETHYLENE GLYCOLS; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84856287802     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3182005783     Document Type: Article

References (14)

1. Rahman ZU, Frye DK, Smith TL, et al. Long-term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin containing chemotherapy: a reference. Cancer. 1999;85:104-111. (Pubitemid 29031363)
2. Greenberg PA, Hortobagyi GN, Smith TL, et al. Long-term follow-up with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14: 2197-2205. (Pubitemid 26264869)
3. Jassem J, Pienkowski T, Pluzanska A, et al. Doxorubicin paclitaxel versus fluorouracil doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a large phase II study. J Clin Oncol. 2001;19:1707-1715. (Pubitemid 32230871)
4. Nabholtz JM, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter phase III trial. J Clin Oncol. 2003;21:968-975. (Pubitemid 46594123)
5. Gabizon A, Martin F. Polyethylene glycol-coated liposomal doxorubicin; rationale for use in solid tumors. Drugs. 1997; 54:15-21. (Pubitemid 27487791)
6. Ranson MR, Carmichael J, O'Byrne K, et al. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicentre phase II trial. J Clin Oncol. 1997;15:3185-3191. (Pubitemid 27419330)
7. Lyass O, Uzieli B, Ben-Yosef R, et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin in metastatic breast carcinoma. Cancer. 2000;89:1037-1047.
8. O'Brien M, Wigler N, O'Brien M, et al. Reduced cardiac toxicity and comparable efficacy in phase III trial of pegylated liposomal doxorubicin versus doxorubicin for first line treatment of metastatic breast cancer. Ann Oncol. 2004;15:440-449. (Pubitemid 38444547)
9. Carmichael J, Possinger K, Philip P, et al. Advanced breast cancer a phase II study with Gemcitabine. J Clin Oncol. 1995;13: 2731-2736.
10. Blackstein M, Vogel CL, Ambinder R, et al. Gemcitabine as first line therapy in patients with metastatic breast cancer: a phase II trial. Oncology. 2002;62:2-8. (Pubitemid 34124219)
11. Rivera E, Valero V, Syrewicz L, et al. Phase I study of stealth liposomal doxorubicin in combination in the treatment of patients with metastatic breast cancer. J Clin Oncol. 2001;19: 1716-1722. (Pubitemid 32230872)
12. D'Agostino G, Ferrandina G, Garganese G, et al. Phase I study of gemcitabine and liposomal doxorubicin in relapsed ovarian cancer. Oncology. 2002;62:110-114. (Pubitemid 34253079)
13. Trudeau M, Clemons MJ, Provencher L, et al. Phase II multicenter trial of rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines. J Clin Oncol. 2009;22:2504-2508.
14. Miller K, Wang M, Gralow J, et al. Paclitaxel bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666-2676.